|
|
|
Insider
Information: |
Diaz Paul J |
Relationship: |
President and CEO, Dir... |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
1,245,906 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$29,210,106 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
1,245,906 |
|
|
Total
Value |
$29,210,106 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
4
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
36.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Kindred Healthcare Inc |
KND |
Director |
2018-07-02 |
0 |
2003-07-22 |
0 |
Premium* |
|
PharMerica Corporation |
PMC |
Director |
2007-07-31 |
163,671 |
2007-07-31 |
0 |
Premium* |
|
Davita Healthcare Partners |
DVA |
Director |
2023-05-15 |
16,069 |
2007-09-30 |
0 |
Premium* |
|
Myriad Genetics Inc |
MYGN |
President and CEO, Dir... |
2024-05-15 |
1,066,166 |
2020-08-13 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
268 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 11 of 11
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
KND |
Kindred Healthcare Inc |
CEO |
|
2013-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
675,060 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2021-09-23 |
4 |
D |
$34.76 |
$1,716,796 |
D/D |
(49,390) |
796,098 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2021-09-23 |
4 |
A |
$0.00 |
$0 |
D/D |
445,439 |
845,488 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2022-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
234,271 |
1,030,369 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2024-05-15 |
4 |
S |
$25.07 |
$1,880,415 |
D/D |
(75,000) |
1,066,166 |
0 |
% |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2022-08-13 |
4 |
D |
$27.61 |
$1,997,584 |
D/D |
(72,350) |
1,087,079 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2024-05-14 |
4 |
S |
$25.21 |
$2,394,798 |
D/D |
(95,000) |
1,141,166 |
0 |
% |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2023-08-13 |
4 |
D |
$17.89 |
$1,328,064 |
D/D |
(74,235) |
1,144,396 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2022-03-24 |
4 |
D |
$25.32 |
$1,116,207 |
D/D |
(44,084) |
1,159,429 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President & CEO |
|
2022-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
173,144 |
1,203,513 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2023-03-24 |
4 |
D |
$23.72 |
$1,077,481 |
D/D |
(45,425) |
1,218,631 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2024-05-13 |
4 |
S |
$25.13 |
$1,453,550 |
D/D |
(57,844) |
1,236,166 |
0 |
% |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2023-03-22 |
4 |
D |
$22.91 |
$459,254 |
D/D |
(20,046) |
1,264,056 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
197,023 |
1,284,102 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2024-03-24 |
4 |
D |
$22.24 |
$1,019,081 |
D/D |
(45,822) |
1,294,010 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2024-03-22 |
4 |
D |
$22.24 |
$449,292 |
D/D |
(20,202) |
1,339,832 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2024-03-15 |
4 |
D |
$21.16 |
$647,708 |
D/D |
(30,610) |
1,360,034 |
0 |
- |
|
MYGN |
Myriad Genetics Inc |
President and CEO |
|
2024-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
246,248 |
1,390,644 |
0 |
- |
|
268 Records found
|
|
Page 11 of 11 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|